These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28528764)

  • 21. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of a tetravalent dengue vaccine in healthy children aged 2-11 years in Malaysia: a randomized, placebo-controlled, Phase III study.
    Hss AS; Koh MT; Tan KK; Chan LG; Zhou L; Bouckenooghe A; Crevat D; Hutagalung Y
    Vaccine; 2013 Dec; 31(49):5814-21. PubMed ID: 24135573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dengue vaccine and the 2016 Olympics.
    Halstead SB; Aguiar M
    Lancet; 2016 Jul; 388(10041):237-8. PubMed ID: 27479569
    [No Abstract]   [Full Text] [Related]  

  • 24. Efficacy of a tetravalent dengue vaccine in children in Latin America.
    Villar L; Dayan GH; Arredondo-García JL; Rivera DM; Cunha R; Deseda C; Reynales H; Costa MS; Morales-Ramírez JO; Carrasquilla G; Rey LC; Dietze R; Luz K; Rivas E; Miranda Montoya MC; Cortés Supelano M; Zambrano B; Langevin E; Boaz M; Tornieporth N; Saville M; Noriega F;
    N Engl J Med; 2015 Jan; 372(2):113-23. PubMed ID: 25365753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate.
    Gessner BD; Wilder-Smith A
    Vaccine; 2016 Apr; 34(20):2397-401. PubMed ID: 27055020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a recombinant, chimeric tetravalent dengue vaccine candidate.
    Osorio JE; Partidos CD; Wallace D; Stinchcomb DT
    Vaccine; 2015 Dec; 33(50):7112-20. PubMed ID: 26585500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.
    Guy B; Jackson N
    Nat Rev Microbiol; 2016 Jan; 14(1):45-54. PubMed ID: 26639777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination.
    Whitehead SS; Durbin AP; Pierce KK; Elwood D; McElvany BD; Fraser EA; Carmolli MP; Tibery CM; Hynes NA; Jo M; Lovchik JM; Larsson CJ; Doty EA; Dickson DM; Luke CJ; Subbarao K; Diehl SA; Kirkpatrick BD
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005584. PubMed ID: 28481883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.
    Sabchareon A; Wallace D; Sirivichayakul C; Limkittikul K; Chanthavanich P; Suvannadabba S; Jiwariyavej V; Dulyachai W; Pengsaa K; Wartel TA; Moureau A; Saville M; Bouckenooghe A; Viviani S; Tornieporth NG; Lang J
    Lancet; 2012 Nov; 380(9853):1559-67. PubMed ID: 22975340
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dengue vaccines: Are they safe for travelers?
    Halstead SB; Aguiar M
    Travel Med Infect Dis; 2016; 14(4):378-83. PubMed ID: 27343438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Symptomatic Dengue Disease in Five Southeast Asian Countries: Epidemiological Evidence from a Dengue Vaccine Trial.
    Nealon J; Taurel AF; Capeding MR; Tran NH; Hadinegoro SR; Chotpitayasunondh T; Chong CK; Wartel TA; Beucher S; Frago C; Moureau A; Simmerman M; Laot T; L'Azou M; Bouckenooghe A
    PLoS Negl Trop Dis; 2016 Aug; 10(8):e0004918. PubMed ID: 27532617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety concerns derail dengue vaccination program.
    Normile D
    Science; 2017 Dec; 358(6370):1514-1515. PubMed ID: 29269451
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and immunogenicity of a recombinant tetravalent dengue vaccine in 9-16 year olds: a randomized, controlled, phase II trial in Latin America.
    Villar LÁ; Rivera-Medina DM; Arredondo-García JL; Boaz M; Starr-Spires L; Thakur M; Zambrano B; Miranda MC; Rivas E; Dayan GH
    Pediatr Infect Dis J; 2013 Oct; 32(10):1102-9. PubMed ID: 24067553
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects.
    Guy B; Nougarede N; Begue S; Sanchez V; Souag N; Carre M; Chambonneau L; Morrisson DN; Shaw D; Qiao M; Dumas R; Lang J; Forrat R
    Vaccine; 2008 Oct; 26(45):5712-21. PubMed ID: 18762226
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tropical diseases. Dengue vaccine trial poses public health quandary.
    Normile D
    Science; 2014 Jul; 345(6195):367-8. PubMed ID: 25061184
    [No Abstract]   [Full Text] [Related]  

  • 36. Tropical diseases. Hunt for dengue vaccine heats up as the disease burden grows.
    Normile D
    Science; 2007 Sep; 317(5844):1494-5. PubMed ID: 17872423
    [No Abstract]   [Full Text] [Related]  

  • 37. Sanofi’s successful Phase 3 trials may lead to first-ever dengue vaccine in 2015.
    Hum Vaccin Immunother; 2014; 10(12):3427. PubMed ID: 25864560
    [No Abstract]   [Full Text] [Related]  

  • 38. Dengue vaccine development: strategies and challenges.
    Ramakrishnan L; Pillai MR; Nair RR
    Viral Immunol; 2015 Mar; 28(2):76-84. PubMed ID: 25494228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection.
    Pitisuttithum P; Bouckenooghe A
    Expert Rev Vaccines; 2016 Jul; 15(7):795-8. PubMed ID: 27171845
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.